AZN - Spark Newswire

3 minute read

Events
News

AstraZeneca Announced Imfinzi and Tremelimumab With Chemotherapy Demonstrated Sustained Survival Benefit in Metastatic Non-small Cell Lung Cancer, Nearly Doubling the Number of Patients Alive After Three Years vs Chemotherapy

Today, 11:06 AM

Exploratory analysis from POSEIDON Phase III trial also showed trends for overall survival benefit with a limited course of tremelimumab added to Imfinzi and chemotherapy in subgroups with high unmet need

AZN

5 minute read

News

AstraZeneca Announced Enhertu Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer

By Charles Gross

Today, 11:06 AM

Updated results from DESTINY-Lung01 Phase II trial demonstrate continued durable activity across patient subtypes

AZN

3 minute read

Important Biotech Catalysts For September 9, 2022 – End Of The Day Summary

By Ragothaman Srinivasan

Today, 11:06 AM

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to…

ADAP

1 minute read

AstraZeneca-Merck’s Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer

By Vandana Singh

Today, 11:06 AM

AstraZeneca plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK) announced long-term follow-up results from the Phase 3 PAOLA-1 and SOLO-1 trials in first-line…

AZN

1 minute read

AstraZeneca And Merck Announce Long-Term Follow Up Results From Phase 3 PAOLA-1 And SOLO-1 Trials

By Bill Haddad

Today, 11:06 AM

Five-year follow-up of the Phase 3 PAOLA-1 trial showed LYNPARZA plus bevacizumab provided a clinically meaningful improvement in overall survival in a subgroup of HRD-positive patients, with 65.5% of patients

AZN

2 minute read

News

Ionis and Astrazeneca’s Eplontersen Demonstrated a Statistically Significant and Clinically Meaningful Change From Baseline for Co-primary and Secondary Endpoints at 35 Weeks vs External Placebo Group

By Charles Gross

Today, 11:06 AM

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a planned 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

AZN